• FirefoxUpgrade to the new Firefox »
  •  Dow Down0.79% Nasdaq Up0.16%

    Portola Pharmaceuticals, Inc. (PTLA)

    28.16 Up 0.16(0.57%) Jan 23, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Portola Pharmaceuticals, Inc.
    270 East Grand Avenue
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-246-7300
    Fax: 650-246-7376
    Website: http://www.portola.com

    Index Membership:N/A
    Full Time Employees:70

    Business Summary 

    Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. The company’s lead development candidate, Andexanet Alfa, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Andexanet Alfa focuses on entering into Phase III registration studies. It has clinical collaboration agreements with various manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb Company, Pfizer Inc., Bayer Pharma, AG, Janssen Pharmaceuticals, Inc., and Daiichi Sankyo, Inc. The company is also developing Cerdulatinib, which is in Phase I/II proof-of-concept study, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases enzymes that regulate signaling pathways, as well as for hematologic, or blood, cancers, and inflammatory disorders. In addition, it is involved in the development of PRT2607, a selective Syk inhibitor. The company was founded in 2003 and is headquartered in South San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Portola Pharmaceuticals, Inc.

    Corporate Governance 
    Portola Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jan 1, 2015 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 6; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. William Lis , 50
    Chief Exec. Officer and Director
    Ms. Mardi C. Dier , 51
    Chief Financial Officer, Principal Accounting Officer and Exec. VP
    Dr. John T. Curnutte M.D., Ph.D., 63
    Exec. VP of R&D
    Mr. Jeet Mahal ,
    VP of Bus. Devel.
    Mr. Peter M. Strumph , 50
    Sr. VP of Clinical and Small Molecule Technical Operations
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders